IMIPENEM/CILASTATIN/RELEBACTAM
Added to formulary October 2021. It is restricted to infectious disease and use should be considered after a patient fails previous gram-negative therapy.
Added to formulary October 2021. It is restricted to infectious disease and use should be considered after a patient fails previous gram-negative therapy.